Host cell protein characterisation during the downstream processing of monoclonal antibodies from mammalian cells
The biopharmaceutical industry is at a pivotal moment of its short history, with ‘blockbuster’ monoclonal antibody (mAb) biosimilars emerging and the ‘next generation’ of molecules beginning to make their mark. Concomitantly, regulatory constraints on manufacturers have amplified, with processes now...
| Main Author: | |
|---|---|
| Published: |
University College London (University of London)
2014
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.626660 |